{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:18:57Z","timestamp":1792041537368,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11910-022-01235-1","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T11:04:36Z","timestamp":1666350276000},"page":"709-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Vascular Considerations for Amyloid Immunotherapy"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-238X","authenticated-orcid":false,"given":"Kate E.","family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-1564","authenticated-orcid":false,"given":"Donna M.","family":"Wilcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"1","key":"1235_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","volume":"5","author":"H Hippius","year":"2003","unstructured":"Hippius H, Neundorfer G. The discovery of Alzheimer\u2019s disease. Dialogues Clin Neurosci. 2003;5(1):101\u20138.","journal-title":"Dialogues Clin Neurosci"},{"issue":"6311","key":"1235_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704\u20136. https:\/\/doi.org\/10.1038\/349704a0.","journal-title":"Nature"},{"issue":"5054","key":"1235_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135. https:\/\/doi.org\/10.1126\/science.1566067.","journal-title":"Science"},{"issue":"5","key":"1235_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00005072-199409000-00003","volume":"53","author":"DJ Selkoe","year":"1994","unstructured":"Selkoe DJ. Alzheimer\u2019s disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994;53(5):438\u201347. https:\/\/doi.org\/10.1097\/00005072-199409000-00003.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"41","key":"1235_CR5","doi-asserted-by":"publisher","first-page":"23895","DOI":"10.1074\/jbc.270.41.23895","volume":"270","author":"CJ Pike","year":"1995","unstructured":"Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of \u03b2-amyloid peptides in vitro. J Biol Chem. 1995;270(41):23895\u20138. https:\/\/doi.org\/10.1074\/jbc.270.41.23895.","journal-title":"J Biol Chem"},{"issue":"1","key":"1235_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994;13(1):45\u201353. https:\/\/doi.org\/10.1016\/0896-6273(94)90458-8.","journal-title":"Neuron"},{"issue":"12","key":"1235_CR7","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/00004647-200012000-00005","volume":"20","author":"K Niwa","year":"2000","unstructured":"Niwa K, Carlson GA, Iadecola C. Exogenous A\u03b21\u201340 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab. 2000;20(12):1659\u201368. https:\/\/doi.org\/10.1097\/00004647-200012000-00005.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10","key":"1235_CR8","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1161\/strokeaha.109.559641","volume":"40","author":"M Gomis","year":"2009","unstructured":"Gomis M, Sobrino TS, Ois A, Mill\u00e1N MN, Rodr\u00edGuez-Campello A, De La Ossa NPR, et al. Plasma \u03b2-amyloid 1\u201340 is associated with the diffuse small vessel disease subtype. Stroke. 2009;40(10):3197\u2013201. https:\/\/doi.org\/10.1161\/strokeaha.109.559641.","journal-title":"Stroke"},{"issue":"1","key":"1235_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1073\/pnas.93.1.452","volume":"93","author":"B Solomon","year":"1996","unstructured":"Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci. 1996;93(1):452\u20135. https:\/\/doi.org\/10.1073\/pnas.93.1.452.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"1235_CR10","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","volume":"94","author":"B Solomon","year":"1997","unstructured":"Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A. 1997;94(8):4109\u201312. https:\/\/doi.org\/10.1073\/pnas.94.8.4109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6740","key":"1235_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173\u20137. https:\/\/doi.org\/10.1038\/22124. This paper is the first article showing effective immunization procedures to clear A\u03b2 plaques in mice.","journal-title":"Nature"},{"issue":"6815","key":"1235_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A\u03b2 peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. Nature. 2000;408(6815):982\u20135. https:\/\/doi.org\/10.1038\/35050116.","journal-title":"Nature"},{"issue":"6815","key":"1235_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A\u03b2 peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease. Nature. 2000;408(6815):979\u201382. https:\/\/doi.org\/10.1038\/35050110.","journal-title":"Nature"},{"issue":"24","key":"1235_CR14","doi-asserted-by":"publisher","first-page":"21562","DOI":"10.1074\/jbc.M100710200","volume":"276","author":"MA Chishti","year":"2001","unstructured":"Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276(24):21562\u201370. https:\/\/doi.org\/10.1074\/jbc.M100710200.","journal-title":"J Biol Chem"},{"issue":"8","key":"1235_CR15","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916\u20139. https:\/\/doi.org\/10.1038\/78682. The authors show the first murine demonstration that peripheral immunization of anti-A\u03b2 antibodies can cross the cerebrovasculature to mitigate A\u03b2 plaque.","journal-title":"Nat Med"},{"key":"1235_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. https:\/\/doi.org\/10.3389\/fimmu.2014.00520.","journal-title":"Front Immunol"},{"issue":"2","key":"1235_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/antib8020030","volume":"8","author":"SW De Taeye","year":"2019","unstructured":"De Taeye SW, Rispens T, Vidarsson G. The ligands for human IgG and their effector functions. Antibodies. 2019;8(2):30. https:\/\/doi.org\/10.3390\/antib8020030.","journal-title":"Antibodies"},{"issue":"18","key":"1235_CR18","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","volume":"22","author":"BJ Bacskai","year":"2002","unstructured":"Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002;22(18):7873\u20138.","journal-title":"J Neurosci"},{"issue":"4","key":"1235_CR19","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"F Bard","year":"2003","unstructured":"Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to \u03b2-amyloid peptide for protection against Alzheimer\u2019s disease-like neuropathology. Proc Natl Acad Sci. 2003;100(4):2023\u20138. https:\/\/doi.org\/10.1073\/pnas.0436286100.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"1235_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/pro.352","volume":"19","author":"S Lightle","year":"2010","unstructured":"Lightle S, Aykent S, Lacher N, Mitaksov V, Wells K, Zobel J, et al. Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. Protein Sci. 2010;19(4):753\u201362. https:\/\/doi.org\/10.1002\/pro.352.","journal-title":"Protein Sci"},{"issue":"9","key":"1235_CR21","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1523\/JNEUROSCI.23-09-03745.2003","volume":"23","author":"DM Wilcock","year":"2003","unstructured":"Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23(9):3745\u201351.","journal-title":"J Neurosci"},{"issue":"1","key":"1235_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","volume":"15","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004;15(1):11\u201320. https:\/\/doi.org\/10.1016\/j.nbd.2003.09.015.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"1235_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1006\/exnr.1997.6738","volume":"149","author":"DA DeWitt","year":"1998","unstructured":"DeWitt DA, Perry G, Cohen M, Doller C, Silver J. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer\u2019s disease. Exp Neurol. 1998;149(2):329\u201340. https:\/\/doi.org\/10.1006\/exnr.1997.6738.","journal-title":"Exp Neurol"},{"issue":"4","key":"1235_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nm838","volume":"9","author":"T Wyss-Coray","year":"2003","unstructured":"Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9(4):453\u20137. https:\/\/doi.org\/10.1038\/nm838.","journal-title":"Nat Med"},{"issue":"15","key":"1235_CR25","doi-asserted-by":"publisher","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2001;98(15):8850\u20135. https:\/\/doi.org\/10.1073\/pnas.151261398.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5563","key":"1235_CR26","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1126\/science.1067568","volume":"295","author":"RB DeMattos","year":"2002","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer\u2019s disease. Science. 2002;295(5563):2264\u20137. https:\/\/doi.org\/10.1126\/science.1067568.","journal-title":"Science"},{"issue":"5597","key":"1235_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298(5597):1379. https:\/\/doi.org\/10.1126\/science.1078259.","journal-title":"Science"},{"issue":"1","key":"1235_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1742-2094-1-24","volume":"1","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1(1):24. https:\/\/doi.org\/10.1186\/1742-2094-1-24.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"1235_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25(3):629\u201336. https:\/\/doi.org\/10.1523\/JNEUROSCI.4337-04.2005.","journal-title":"J Neurosci"},{"issue":"5\u20136","key":"1235_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s007020200068","volume":"109","author":"KA Jellinger","year":"2002","unstructured":"Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm. 2002;109(5\u20136):813\u201336. https:\/\/doi.org\/10.1007\/s007020200068.","journal-title":"J Neural Transm"},{"issue":"6","key":"1235_CR31","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1007\/s12035-015-9319-7","volume":"53","author":"C Janota","year":"2016","unstructured":"Janota C, Lemere CA, Brito MA. Dissecting the contribution of vascular alterations and aging to Alzheimer\u2019s disease. Mol Neurobiol. 2016;53(6):3793\u2013811. https:\/\/doi.org\/10.1007\/s12035-015-9319-7.","journal-title":"Mol Neurobiol"},{"issue":"10","key":"1235_CR32","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nrn938","volume":"3","author":"D Schenk","year":"2002","unstructured":"Schenk D. Amyloid-\u03b2 immunotherapy for Alzheimer\u2019s disease: the end of the beginning. Nat Rev Neurosci. 2002;3(10):824\u20138. https:\/\/doi.org\/10.1038\/nrn938.","journal-title":"Nat Rev Neurosci"},{"issue":"44","key":"1235_CR33","doi-asserted-by":"publisher","first-page":"11437","DOI":"10.1523\/jneurosci.2436-06.2006","volume":"26","author":"MS Buckwalter","year":"2006","unstructured":"Buckwalter MS, Coleman BS, Buttini M, Barbour R, Schenk D, Games D, et al. Increased T cell recruitment to the CNS after amyloid beta1-42 immunization in Alzheimer\u2019s mice overproducing transforming growth factor-beta1. J Neurosci. 2006;26(44):11437\u201341. https:\/\/doi.org\/10.1523\/jneurosci.2436-06.2006.","journal-title":"J Neurosci"},{"issue":"1","key":"1235_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer I, Rovira MB, Guerra MLS, Rey MJ, Costa-Juss\u00e1 F. Neuropathology and pathogenesis of encephalitis following amyloid \u03b2 immunization in Alzheimer\u2019s disease. Brain Pathol. 2004;14(1):11\u201320. https:\/\/doi.org\/10.1111\/j.1750-3639.2004.tb00493.x.","journal-title":"Brain Pathol"},{"issue":"4","key":"1235_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JAR Nicoll","year":"2003","unstructured":"Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-\u03b2 peptide: a case report. Nat Med. 2003;9(4):448\u201352. https:\/\/doi.org\/10.1038\/nm840.","journal-title":"Nat Med"},{"issue":"11","key":"1235_CR36","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JAR Nicoll","year":"2006","unstructured":"Nicoll JAR, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. A\u03b2 species removal after A\u03b2<sub>42<\/sub>immunization. J Neuropathol Exp Neurol. 2006;65(11):1040\u20138. https:\/\/doi.org\/10.1097\/01.jnen.0000240466.10758.ce.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Pt 12","key":"1235_CR37","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"D Boche","year":"2008","unstructured":"Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain. Brain. 2008;131(Pt 12):3299\u2013310. https:\/\/doi.org\/10.1093\/brain\/awn261.","journal-title":"Brain"},{"issue":"24","key":"1235_CR38","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/wnl.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061\u201370. https:\/\/doi.org\/10.1212\/wnl.0b013e3181c67808.","journal-title":"Neurology"},{"issue":"4","key":"1235_CR39","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/nejmoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):322\u201333. https:\/\/doi.org\/10.1056\/nejmoa1304839.","journal-title":"N Engl J Med"},{"key":"1235_CR40","doi-asserted-by":"publisher","unstructured":"Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimer\u2019s Res Ther. 2016;8(1). https:\/\/doi.org\/10.1186\/s13195-016-0189-7.","DOI":"10.1186\/s13195-016-0189-7"},{"issue":"2","key":"1235_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/wad.0b013e3181c53b00","volume":"24","author":"RS Black","year":"2010","unstructured":"Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24(2):198\u2013203. https:\/\/doi.org\/10.1097\/wad.0b013e3181c53b00.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"1235_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363\u201372. https:\/\/doi.org\/10.1016\/S1474-4422(10)70043-0.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1235_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):311\u201321. https:\/\/doi.org\/10.1056\/nejmoa1312889.","journal-title":"N Engl J Med"},{"issue":"4","key":"1235_CR44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367\u201385. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2351.","journal-title":"Alzheimers Dement"},{"key":"1235_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2021-7-3","volume":"10","author":"RR Tampi","year":"2021","unstructured":"Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs in Context. 2021;10:1\u20139. https:\/\/doi.org\/10.7573\/dic.2021-7-3.","journal-title":"Drugs in Context"},{"key":"1235_CR46","unstructured":"Food and Drug Administration, Biogen. Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee Meeting. 2020."},{"issue":"7618","key":"1235_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136. https:\/\/doi.org\/10.1038\/nature19323.","journal-title":"Nature"},{"key":"1235_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-804832-0.00002-X","volume-title":"Biomarkers in Alzheimer's Disease","author":"TK Khan","year":"2016","unstructured":"Khan TK. Chapter 2 - Clinical diagnosis of Alzheimer\u2019s disease. In: Khan TK, editor. Biomarkers in Alzheimer\u2019s Disease. Academic Press; 2016. p. 27\u201348."},{"issue":"4","key":"1235_CR49","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17(4):696\u2013701. https:\/\/doi.org\/10.1002\/alz.12213. This paper outlines the timeline of clinical trials for aducanumab and FDA statements as well as highlights the areas where outcome measures fell short statistically and translationally. This subjective piece details the need for a third clinical trial since EMERGE and ENGAGE failed to provide evidence of efficacy.","journal-title":"Alzheimers Dement"},{"key":"1235_CR50","doi-asserted-by":"publisher","unstructured":"Haeberlein SB, Von Hehn C, Tian Y, Chalkias S, Muralidharan KK, Chen T, et al. Emerge and Engage topline results: phase 3 studies of aducanumab in early Alzheimer\u2019s disease. Alzheimer's & Dementia. 2020;16(S9). https:\/\/doi.org\/10.1002\/alz.047259.","DOI":"10.1002\/alz.047259"},{"issue":"4","key":"1235_CR51","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8(4):398\u2013410. https:\/\/doi.org\/10.14283\/jpad.2021.41.","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"1235_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.14283\/jpad.2022.34","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221\u201330. https:\/\/doi.org\/10.14283\/jpad.2022.34. This article updates the appropriate use of aducanumab in the clinic. The authors outline the recommendations of patient population selection and clinical safety monitoring of ARIA events.","journal-title":"J Prev Alzheimers Dis"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-022-01235-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T11:44:44Z","timestamp":1667475884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-022-01235-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s11910-022-01235-1","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"18 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}